225 related articles for article (PubMed ID: 2344163)
1. In vitro and in vivo activities of a new quinolone, WIN 57273, possessing potent activity against gram-positive bacteria.
Sedlock DM; Dobson RA; Deuel DM; Lesher GY; Rake JB
Antimicrob Agents Chemother; 1990 Apr; 34(4):568-75. PubMed ID: 2344163
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo evaluations of A-80556, a new fluoroquinolone.
Clement JJ; Tanaka SK; Alder J; Vojtko C; Beyer J; Hensey D; Ramer N; McDaniel D; Chu DT
Antimicrob Agents Chemother; 1994 May; 38(5):1071-8. PubMed ID: 8067740
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections.
Bongaerts GP; Hoogkamp-Korstanje JA
Antimicrob Agents Chemother; 1993 Sep; 37(9):2017-9. PubMed ID: 8239624
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of BAY 12-8039, a new fluoroquinolone.
Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro activity of lomefloxacin, a difluoro-quinolone.
Robbins MJ; Baskerville AJ; Sanghrajka M; Mumtaz G; Felmingham D; Ridgway GL; Grüneberg RN
Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):65S-76S. PubMed ID: 2791500
[TBL] [Abstract][Full Text] [Related]
6. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.
Fung-Tomc J; Minassian B; Kolek B; Washo T; Huczko E; Bonner D
J Antimicrob Chemother; 2000 Apr; 45(4):437-46. PubMed ID: 10747819
[TBL] [Abstract][Full Text] [Related]
7. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). I. Susceptibility distribution].
Kumamoto Y; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Kitagawa R; Igari J; Oguri T; Kosakai N; Yamaguchi K; Kashitani F; Yonezu S; Yamanaka Y; Takaha M; Iori F
Jpn J Antibiot; 1996 May; 49(5):465-93. PubMed ID: 8752862
[TBL] [Abstract][Full Text] [Related]
8. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
McCarter YS; Mazens-Sullivan MF; Bartlett RC
Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.
Nakamura S; Minami A; Nakata K; Kurobe N; Kouno K; Sakaguchi Y; Kashimoto S; Yoshida H; Kojima T; Ohue T
Antimicrob Agents Chemother; 1989 Aug; 33(8):1167-73. PubMed ID: 2802544
[TBL] [Abstract][Full Text] [Related]
10. In-vitro activity of four new fluoroquinolones.
García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone.
Jones RN; Barry AL
Antimicrob Agents Chemother; 1990 Feb; 34(2):306-13. PubMed ID: 2327779
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.
Gootz TD; Brighty KE; Anderson MR; Schmieder BJ; Haskell SL; Sutcliffe JA; Castaldi MJ; McGuirk PR
Diagn Microbiol Infect Dis; 1994 Aug; 19(4):235-43. PubMed ID: 7851087
[TBL] [Abstract][Full Text] [Related]
13. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
[TBL] [Abstract][Full Text] [Related]
14. [In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone].
Nomura N; Mitsuyama J; Furuta Y; Yamada H; Nakata M; Fukuda T; Yamada H; Takahata M; Minami S
Jpn J Antibiot; 2002 Aug; 55(4):412-39. PubMed ID: 12378871
[TBL] [Abstract][Full Text] [Related]
15. Lomefloxacin, a new difluoroquinolone: in vitro activity against gram-positive and gram-negative bacteria.
Hoban D; Grabowski M; Koss J; Weselowski V
Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):77S-82S. PubMed ID: 2791502
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
Nishino T; Otsuki M; Hatano K; Nishihara Y
Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of DV-7751a, a new fluoroquinolone.
Tanaka M; Hoshino K; Ishida H; Sato K; Hayakawa I; Osada Y
Antimicrob Agents Chemother; 1993 Oct; 37(10):2112-8. PubMed ID: 8257132
[TBL] [Abstract][Full Text] [Related]
18. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
Ismaeel NA; Tayeb OS
Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
[TBL] [Abstract][Full Text] [Related]
19. In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates.
Tanaka M; Yamazaki E; Chiba M; Yoshihara K; Akasaka T; Takemura M; Sato K
Antimicrob Agents Chemother; 2002 Mar; 46(3):904-8. PubMed ID: 11850285
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative.
Fukuoka Y; Ikeda Y; Yamashiro Y; Takahata M; Todo Y; Narita H
Antimicrob Agents Chemother; 1993 Mar; 37(3):384-92. PubMed ID: 8460909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
